« Back
Home /
Apilimod (mesylate)

Apilimod (mesylate)

Item no.	HY-14644A-50mg
Manufacturer	MedChem Express
CASRN	870087-36-8
Amount	50 mg
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.83
Formula	C25H34N6O8S2
Citations	bioRxiv. 2023 Aug 12. bioRxiv. 2024 Jan 23. Biomaterials. 2022 Jun;285:121509. bioRxiv. 2020 Apr 21;2020.04.21.053058. bioRxiv. 2023 Apr 28. bioRxiv. 2023 Aug 12. bioRxiv. 2023 Aug 28. bioRxiv. 2023 Oct 20:2023.10.19.563158. bioRxiv. 2024 May 10. biorxiv. 2024 May 27. Biotechnol J. 2022 Dec 7;e2200147. Br J Cancer. 2020 Aug;123(4):542-555. Cancer Lett. 2023 Oct 6:216435. Cell Mol Life Sci. 2016 Dec;73(24):4717-4737. Commun Biol. 2022 Mar 24;5(1):262. Exp Mol Med. 2024 Aug 1. J Biol Chem. 2022 Dec 6;102775. J Cell Biol. 2025 Feb 3;224(2):e202401136. J Virol. 2021 Aug 18;JVI0097521. Mol Biol Cell. 2022 Jan 12;mbcE21060309. Mol Cell Biol. 2025 Feb 2:1-17. Nat Commun. 2020 Mar 27;11(1):1620. PLoS Pathog. 2023 Feb 24;19(2):e1011202. PLoS Pathog. 2025 Jan 2;21(1):e1012800. Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2307423120. Proc Natl Acad Sci U S A. 2024 May 21;121(21):e2403685121. Sci Adv. 2022 Jul 22;8(29):eabn1440. Sci Adv. 2023 Oct 13;9(41):eadh1134. SSRN. 2024 Jan 26. Theranostics. 2020 Mar 4;10(9):3925-3938. Viruses. 2021 Jun 28;13(7):1255. Viruses. 2023 Jun 12, 15(6), 1353. [1]Wada Y, et al. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood. 2007 Feb 1;109(3):1156-64. [2]Billich A. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.IDrugs. 2007 Jan;10(1):53-9. [3]Keino H, et al. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10(5):R122.
Smiles	CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC4=CC=CC=N4)=N2)=C1.CS(=O)(O)=O.CS(=O)(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	STA 5326 (mesylate); LAM-002A; AIT-101 (mesylate)
Similar products	870087-36-8
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Interleukin Related; PIKfyve
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	610.70
Product Description	Apilimod (STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively[1]. Apilimod is a potent and highly selective PIKfyve inhibitor.
Manufacturer - Research Area	Inflammation/Immunology; Cancer
Solubility	DMSO : 12.5 mg/mL (ultrasonic)\|H2O : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Immunology/Inflammation; PI3K/Akt/mTOR
Isoform	IL-12; IL-23; IL-4; IL-5; IL-8
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-14644A-50mg-safety-datasheet.pdf